For many years, the biggest threat to marijuana legalization and fledgling legal cannabis businesses was the police.
Fears of DEA agents breaking down the front door at dawn, prosecutions in federal court with its accompanying mandatory minimums or warrantless visits from helicopter-riding police who merely cut down plant and leave—such things happen and are legal—was what kept people involved in cannabis up at night.
But now, with legalization sweeping the country and a vast majority of Americans in support of medical marijuana, the real enemy is revealing itself.
In 2015, U.S.-based companies made up 40 percent of the global pharmaceutical trade, a market share worth $413 billion. These companies are well aware that cannabis is becoming an accepted treatment for chronic pain and many of the other lifelong afflictions now treated by highly profitable trademarked drugs—and some have proven willing and able to take steps to make sure marijuana stays out of the hands of law-abiding Americans in order to protect that enormous bottom line.
“Pharmaceuticals are going to run me down,” Dr. Gina Berman, medical director of the Giving Tree Wellness Center, a Phoenix, Arizona-based cannabis dispensary, told the Guardian. “We have a small business, and we can’t afford to fight Big Pharma.”
The most egregious case to date is Insys Therapeutics. Insys, is an Arizona-based drug manufacturer of pain drugs that contain fentanyl, the powerful synthetic opioid that’s been fingered in many fatal opiate overdoses (including the death of Prince).
Arizona was the lone state where a marijuana legalization initiative failed at the ballot in November—and one of the leading donors to the anti-legalization campaign, with a $500,000 check, was Insys. (Another was Trump-supporting casino magnate Sheldon Adelson, CEO of the Las Vegas Sands Corp. Here are the Vegas nightlife spots to boycott, forever.)
As the Intercept reported this fall, Insys executives openly recognized the threat to its market posed by marijuana. And in a devious twist, Insys identified marijuana as an existential threat and moved to keep it illegal, while developing a new drug based on synthetic THC.
On March 23, the DEA ruled that Insys’s new drug, called “Syndros,” could be marketed and sold as a Schedule II drug—meaning it could be prescribed to patients as soon as this fall.
So far, the FDA has approved Syndros for AIDS-related weight loss and vomiting and nausea associated with chemotherapy—two of the original applications for medical marijuana.
“It’s pretty absurd that federal law considers marijuana to have no medical value, but allows for the development of synthetic versions of the same substance,” Mason Tvert, a spokesman for the Marijuana Policy Project, which sponsored Arizona’s legalization measure, told the Guardian.
But what about Insys Therapeutics? It’s a company straight out of a Superman comic.
In December, Justice Department prosecutors took the “unusual” step of charging six former Insys executives, including former CEO Michael L. Babich, with racketeering for its “aggressive” marketing of a fentanyl-based pain drug called Subsys, the New York Times reported. Prosecutors alleged that in order to sell more Subsys, the company arranged lavish dinners and other events for doctors who prescribed “lots of” the drug, and when that didn’t work, the company resorted to kickbacks.
One Connecticut nurse pleaded guilty in 2015 to accepting $83,000 in kickbacks from the company. Families of dead patients, prescribed Subsys despite prescriptions for other drugs that are fatal when combined, and despite no cancer diagnosis—the drug is only FDA-approved from cancer-related pain—have also sued the company.
In a statement, Carmen Ortiz, the-then U.S. attorney for Massachusetts (before she and many others were summarily fired by Trump administration officials earlier this year), pinned part of the blame for the country’s opiate epidemic squarely on “corporate greed.”
In January, Insys founder John Kapoor stepped down as chairman, a role he took over from the indicted Babich in late 2015. Kapoor’s exit came after Insys’s sales plummeted 40 percent, as Forbes reported. (Wonder if the alleged kickbacks had anything to do with the inflated numbers?)
It’s all very ominous, but in a real way, marijuana activists should let Insys try—and then fail, spectacularly, as they are primed to do.
Insys’s proposed product, called Syndros, is a solution of “oral dronabinol.” Dronabinol is the generic name for another synthetic version of THC that’s been on the market for quite some time, called Marinol—and if you know anyone who has used Marinol, you know what they think of it. Namely, it kind of sucks.
For many patients, fake weed simply doesn’t work. As one patient prescribed Marinol told CBS News, “It might as well have been M&M’s.”
This is almost certainly because as synthetic THC only, Marinol and Syndros both lack cannabidiol, or CBD, as well as dozens of others cannabinoids. And as per the “entourage effect” theory, proffered by luminaries like CNN’s Sanjay Gupta and many more, your body and brain need all of cannabis’s component parts in order for its medical “magic” to work.
But let’s say Insys strikes out with Subsys. It won’t end there.
This is a company accused, with enough evidence to indict in a federal court, of being willing to see people die in order to sell more drugs. And it won’t end with this company.
Big Pharma is scared of weed—terrified—and as any animal scientist will tell you, a cornered and frightened animal is the most dangerous. And that applies to humans.